Rubius Therapeutics

98 articles with Rubius Therapeutics

• Rubius Therapeutics Appoints Dannielle Appelhans as Chief Operating Officer

  7/29/2021

  Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced the appointment of Dannielle Appelhans as chief operating officer, effective August 9, 2021

• Rubius Therapeutics to Announce Second Quarter 2021 Financial Results

  7/22/2021

  Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to report second quarter financial results on Monday, August 9, 2021, before market open.

• Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, Immunotherapy

  7/15/2021

  Rubius Therapeutics, Inc. today announced the publication of preclinical data in the peer-reviewed journal Cancer Immunology, Immunotherapy , for its lead clinical oncology program, RTX-240, for the treatment of adults with advanced solid tumors and relapsed/refractory acute myeloid leukemia.

• Rubius Therapeutics Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of Advanced Solid Tumors

  6/23/2021

  Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that the first patient has been dosed in a new Phase 1 arm of the ongoing Phase 1/2 clinical trial of RTX-240 in combination with KEYTRUDA®

• 

  Flagship Pioneering Takes Aim at Global Health Threats with $3.37 Billion Fund

  6/14/2021

  ​Flagship Pioneering announced a massive cash infusion to support the development and launch of new companies aiming at various diseases and global health threats.

• Rubius Therapeutics to Participate in Jefferies Virtual Healthcare Conference

  5/20/2021

  Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 4:00 p.m. EDT.

• Rubius Therapeutics to Present Trials in Progress Poster on the Phase 1 Clinical Trial of RTX-321 for HPV 16-Positive Cancers at the 2021 American Society of Clinical Oncology Annual Meeting

  5/19/2021

  Rubius Therapeutics, Inc. announced that the Company will present a Trials in Progress poster presentation for its lead artificial antigen-presenting cell program, RTX-321, at the American Society of Clinical Oncology Annual Meeting being held virtually from June 4-8, 2021.

• Rubius Therapeutics Announces Publication of RTX-321 Preclinical Data in Nature CommunicationsPreclinical Data Demonstrate RTX-321 Potently Activates and Expands HPV 16-Reactive Anti-Tumor T Cells and Provides Broad Immune Stimulation

  5/12/2021

  Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, announced the publication of preclinical data in the peer-reviewed journal Nature Communications, for its lead artificial antigen-presenting cell program, RTX-321, for the potential treatment of human papillomavirus 16-positive cancers.

• Rubius Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

  5/10/2021

  Positive Initial Data from Phase 1/2 Trial of RTX-240 in Advanced Solid Tumors Demonstrated Single-Agent Activity Providing Initial Validation of the RED PLATFORM ® ; Dose Optimization and Enrollment Continues Continued Progress in Advancing Clinical Programs with Further Enrollment in Phase 1 RTX-240 Acute Myeloid Leukemia and RTX-321 Advanced HPV 16-Positive Cancer Trials On Track for Several Anticipated Data Milestones and Catalysts in 2021, and Supported by a Strong Balance Sheet

• Rubius Therapeutics to Announce First Quarter 2021 Financial Results

  4/26/2021

  Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to report first quarter financial results on Monday, May 10, 2021,

• Rubius Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of RTX-321 for the Treatment of HPV 16-Positive Cancers

  4/12/2021

  Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that the first patient has been dosed in the Phase 1 clinical trial of RTX-321 for the treatment of human papilloma virus (HPV) 16-postive cancers

• 

  Clinical Catch-Up: April 5-9

  4/12/2021

  It was a relatively quiet week for clinical trial announcements, but there were a few standouts. Read on for more.

• Rubius Therapeutics Presents Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meeting

  4/9/2021

  Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today reprised initial clinical results from its ongoing Phase 1/2 study of RTX-240 in advanced solid tumors at the American Association for Cancer Research (AACR) Virtual Annual Meeting.

• Rubius Therapeutics Prices Upsized Public Offering of Common Stock - Mar 17, 2021

  3/17/2021

  Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, announces the pricing of an upsized underwritten public offering of 6,896,552 shares of its common stock at a public offering price of $29.00 per share.

• Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity

  3/15/2021

  RTX-240 Generated Partial Responses in Metastatic Anal Cancer and Metastatic Uveal Melanoma Patients; No DLTs or Related Grade 3/4 Adverse Events  RTX-240 Promoted Trafficking of NK and T Cells into Tumor Microenvironment Initial Clinical Data Provide Evidence of Broad Potential of RED PLATFORM ® Across Pipeline of Cancer and Autoimmune Programs Company to Host Conference Call Today at 8:00 a.m. EDT

• Rubius Therapeutics Announces Proposed Public Offering of Common Stock

  3/15/2021

  Rubius Therapeutics, Inc. (NASDAQ: RUBY) (“Rubius”), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announces that it has commenced an underwritten public offering of $150 million of shares of its common stock.

• Rubius Therapeutics Announces Webcast to Review Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors

  3/12/2021

  Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that the Company plans to issue a pre-market press release and conduct a webcast on Monday, March 15, 2021

• Rubius Therapeutics to Present Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meeting

  3/10/2021

  Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that the Company will present clinical results from its ongoing Phase 1/2 study of RTX-240 in advanced solid tumors during Week One of the American Association for Cancer Research (AACR) Virtual Annual Meeting

• Rubius Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

  2/23/2021

  Reported Initial Key Takeaways in January 2021 Showing RTX-240 Stimulates Innate and Adaptive Immunity; Additional Clinical Results to be Presented in Early 2021 Escalated the Dose in RTX-240 Phase 1 Clinical Trial in Relapsed/Refractory Acute Myeloid Leukemia Screening Patients in RTX-321 Phase 1 Clinical Trial in Advanced Human Papillomavirus 16-Positive Cancers

• Rubius Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

  2/18/2021

  Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, and the executive management team will participate in a fireside chat at the 10 th Annual SVB Leerink Global Healthcare Conference on February 25,2021